Abstract
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm that requires long-term hematologic control and symptom monitoring. Despite advanced therapies and treatment guidelines, real-world adherence to therapeutic goals and routine symptom assessment remains inconsistent, particularly outside the academic setting. To optimize care, a pharmacist-led clinical support program was implemented at Levine Cancer Institute, a large regional hematologic malignancy center, in collaboration with the integrated institutional Atrium Health Specialty Pharmacy Service (SPS). This program aimed to standardize PV care system-wide by improving hematocrit (Hct) control and supporting symptom burden assessment via Myeloproliferative Neoplasm Symptom Assessment Form (MPN-10) scores. Through diagnosis code screening and identification of patients with Hct ≥ 45%, the SPS pharmacist team provided clinical reviews, pharmacotherapy recommendations, financial access support, and coordinated care, including dispensing medication and providing medication education. Interim analysis demonstrated improved identification of opportunities for optimization, with sustained provider engagement. This model highlights the opportunity for advanced practitioners, including pharmacists, to improve disease control and quality of life for patients with PV.
References
Andrick, B., Mathur, A., Maiers, T., Graham, J., & Vadakara, J. (2020). Pharmacist Versus Physician Provider Management of Hydroxyurea Therapy for Polycythemia Vera (PERMANACE). Blood, 136 (Supplement 1), 44–45.
Chojecki, A. L., DiSogra, K. Y., Arnall, J., Cowgill, N., Soni, A., Packman, C. H., Sanikommu, S. R., Shah, N. A., Ragon, B. K., Knight, T. G., Ai, J., Avalos, B. R., Copelan, E. A., & Grunwald, M. R. (2022). Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF). Leukemia & Lymphoma, 63(6), 1515–1517. https://doi.org/10.1080/10428194.2022.2032037
Ferrari, A., Carobbio, A., Masciulli, A., Ghirardi, A., Finazzi, G., De Stefano, V., Vannucchi, A. M., & Barbui, T. (2019). Clinical outcomes under hydroxyurea treatment in polycythemia vera: A systematic review and meta-analysis. Haematologica, 104(12), 2391–2399. https://doi.org/10.3324/haematol.2019.221234
Gerds, A. T., Gotlib, J., Ali, H., Bose, P., Dunbar, A., Elshoury, A., George, T. I., Gundabolu, K., Hexner, E., Hobbs, G. S., Jain, T., Jamieson, C., Kaesberg, P. R., Kuykendall, A. T., Madanat, Y., McMahon, B., Mohan, S. R., Nadiminti, K. V., Oh, S., Pardanani, A.,…Hochstetler, C. (2022). Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. JNCCN, 20(9), 1033–1062. https://doi.org/10.6004/jnccn.2022.0046
Iurlo, A., Cattaneo, D., Bucelli, C., & Baldini, L. (2020). New Perspectives on Polycythemia Vera: From Diagnosis to Therapy. International Journal of Molecular Sciences, 21(16), 5805. https://doi.org/10.3390/ijms21165805
Marchetti, M., Vannucchi, A. M., Griesshammer, M., Harrison, C., Koschmieder, S., Gisslinger, H., Álvarez-Larrán, A., De Stefano, V., Guglielmelli, P., Palandri, F., Passamonti, F., Barosi, G., Silver, R. T., Hehlmann, R., Kiladjian, J. J., & Barbui, T. (2022). Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. The Lancet. Haematology, 9(4), e301–e311. https://doi.org/10.1016/S2352-3026(22)00046-1
Marchioli, R., Finazzi, G., Specchia, G., Masciulli, A., Mennitto, M. R., & Barbui, T. (2011). The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera. Thrombosis, 2011, 794240. https://doi.org/10.1155/2011/794240
Nurgat, Z., & Lawrence, M. (2022). Management of Myeloproliferative Neoplasms (MPNs). Journal of Oncology Pharmacy Practice, 28(6), 1400–1410. https://doi.org/10.1177/10781552221082293
Tefferi, A., Vannucchi, A. M., & Barbui, T. (2021). Polycythemia vera: Historical oversights, diagnostic details, and therapeutic views. Leukemia, 35(12), 3339–3351. https://doi.org/10.1038/s41375-021-01401-3
Yacoub, A., Mascarenhas, J., Kosiorek, H., Prchal, J. T., Berenzon, D., Baer, M. R., Ritchie, E., Silver, R. T., Kessler, C., Winton, E., Finazzi, M. C., Rambaldi, A., Vannucchi, A. M., Leibowitz, D., Rondelli, D., Arcasoy, M. O., Catchatourian, R., Vadakara, J., Rosti, V., Hexner, E.,…Hoffman, R. (2019). Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood, 134(18), 1498–1509. https://doi.org/10.1182/blood.2019000428
